Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Results Of Patient Rated Asthma Control Test In Comparison To Diary Card Data

This study has been completed.
Information provided by:
GlaxoSmithKline Identifier:
First received: August 10, 2006
Last updated: March 17, 2011
Last verified: March 2011

August 10, 2006
March 17, 2011
May 2006
Not Provided
Number of well controlled patients according to GOAL criteria after 12 week treatment with SFC 50/250 µg bd compared to number of patients achieving an ACT score of 20-25 for the last 4 weeks of treatment period.
Same as current
Complete list of historical versions of study NCT00363480 on Archive Site
  • Change of number of patients achieving an ACT score 20-25 after end of treatment compared to Visit 3
  • Change in Forced Expiratory Volume (FEV1)
  • Change in morning Peak Expiratory Volume (PEF)
Same as current
Not Provided
Not Provided
Results Of Patient Rated Asthma Control Test In Comparison To Diary Card Data
Reaching Asthma Control With Salmeterol/Fluticasone 50/250 µg bd Combination in Steroid Naive or Low Dose Inhaled Corticoid Steroid Patients by Using Asthma Control Test (ACT) Comparison of Patient Self Rating With Diary Card Data.

The majority of asthma patients are not well controlled, despite the availability of asthma medication that could effectively treat the disease. In this study uncontrolled patients who are steroid-naive or on low dose inhaled corticosteroids will be treated with Salmeterol/Fluticasone combination (SFC) 50/250 µg bd. The asthma control test (ACT) will be used to detect differences in the level of asthma control during treatment. The study aims to show a correlation between improvements of ACT und the level of asthma control which will be reached by the patients.

The aim of the study is to show that most of symptomatic asthma patients can reach 'well controlled asthma' with SFC. We get information about ACT in daily practice and physicians are trained to use the asthma control test as a screening tool and for follow up of asthma management. Correlations are expected between the improvements in ACT, Quality of Life and asthma control according to the Gaining Optimal Asthma controL (GOAL) criteria.

Not Provided
Phase 4
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Drug: Fluticasone propionate/salmeterol(50/250µg)
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Not Provided
Not Provided

Inclusion criteria:

  • Diagnosis of asthma
  • Reversibility >12% after inhalation of 200 µg Salbutamol
  • willingness and ability to complete daily record card on daily basis and to measure morning PEF on daily basis
  • 80% compliance in diary card completion asthma control status: Uncontrolled based on the GOAL criteria

Exclusion criteria:

  • Change of asthma medication during the last 4 weeks
  • Asthma exacerbation characterized by use of oral corticoids during the last 3 months Pretreatment with inhaled corticosteroids more than 500 mcg Beclometasondipropionat or equivalent per day or other controller therapy during the last 3 months
  • upper or lower respiratory tract infection during the RUN-IN period moderate or severe asthma exacerbation during the RUN-IN period
  • Non compliance with use of Discus, PEF-meter and incomplete diary card data
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
SAM 106538
Not Provided
Not Provided
Cheri Hudson; Clinical Disclosure Advisor, GSK Clinical Disclosure
Not Provided
Study Director: GSK Clinical Trials, MD GlaxoSmithKline
March 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP